Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases. 2017

Chong Zhao, and Xin Chen, and Changshan Yang, and Dan Zang, and Xiaoying Lan, and Siyan Liao, and Peiquan Zhang, and Jinjie Wu, and Xiaofen Li, and Ningning Liu, and Yuning Liao, and Hongbiao Huang, and Xianping Shi, and Lili Jiang, and Xiuhua Liu, and Q Ping Dou, and Xuejun Wang, and Jinbao Liu
State Key Laboratory of Respiratory Disease, Protein Modification and Degradation Laboratory, Department of Pathophysiology, Guangzhou Medical University, Guangdong 510182, China.

The ubiquitin-proteasome system (UPS) plays a central role in various cellular processes through selectively degrading proteins involved in critical cellular functions. Targeting UPS has been validated as a novel strategy for treating human cancer, as inhibitors of the 20S proteasome catalytic activity are currently in clinical use for treatment of multiple myeloma and other cancers, and the deubiquitinase activity associated with the proteasome is also a valid target for anticancer agents. Recent studies suggested that zinc pyrithione, an FDA-approved antidandruff agent, may have antitumor activity, but the detailed molecular mechanisms remain unclear. Here we report that zinc pyrithione (ZnPT) targets the proteasome-associated DUBs (USP14 and UCHL5) and inhibits their activities, resulting in a rapid accumulation of protein-ubiquitin conjugates, but without inhibiting the proteolytic activities of 20S proteasomes. Furthermore, ZnPT exhibits cytotoxic effects against various cancer cell lines in vitro, selectively kills bone marrow cells from leukemia patients ex vivo, and efficiently inhibits the growth of lung adenocarcinoma cancer cell xenografts in nude mice. This study has identified zinc pyrithione, an FDA-approved pharmacological agent with potential antitumor properties as a proteasomal DUB inhibitor.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007641 Keratolytic Agents Agents that soften, separate, and cause desquamation of the cornified epithelium or horny layer of skin. They are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases. Desquamating Agents,Skin-Peeling Agents,Agents, Desquamating,Agents, Keratolytic,Agents, Skin-Peeling,Skin Peeling Agents
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D009942 Organometallic Compounds A class of compounds of the type R-M, where a C atom is joined directly to any other element except H, C, N, O, F, Cl, Br, I, or At. (Grant & Hackh's Chemical Dictionary, 5th ed) Metallo-Organic Compound,Metallo-Organic Compounds,Metalloorganic Compound,Organometallic Compound,Metalloorganic Compounds,Compound, Metallo-Organic,Compound, Metalloorganic,Compound, Organometallic,Compounds, Metallo-Organic,Compounds, Metalloorganic,Compounds, Organometallic,Metallo Organic Compound,Metallo Organic Compounds
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D005455 Fluorescent Antibody Technique Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy. Antinuclear Antibody Test, Fluorescent,Coon's Technique,Fluorescent Antinuclear Antibody Test,Fluorescent Protein Tracing,Immunofluorescence Technique,Coon's Technic,Fluorescent Antibody Technic,Immunofluorescence,Immunofluorescence Technic,Antibody Technic, Fluorescent,Antibody Technics, Fluorescent,Antibody Technique, Fluorescent,Antibody Techniques, Fluorescent,Coon Technic,Coon Technique,Coons Technic,Coons Technique,Fluorescent Antibody Technics,Fluorescent Antibody Techniques,Fluorescent Protein Tracings,Immunofluorescence Technics,Immunofluorescence Techniques,Protein Tracing, Fluorescent,Protein Tracings, Fluorescent,Technic, Coon's,Technic, Fluorescent Antibody,Technic, Immunofluorescence,Technics, Fluorescent Antibody,Technics, Immunofluorescence,Technique, Coon's,Technique, Fluorescent Antibody,Technique, Immunofluorescence,Techniques, Fluorescent Antibody,Techniques, Immunofluorescence,Tracing, Fluorescent Protein,Tracings, Fluorescent Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Chong Zhao, and Xin Chen, and Changshan Yang, and Dan Zang, and Xiaoying Lan, and Siyan Liao, and Peiquan Zhang, and Jinjie Wu, and Xiaofen Li, and Ningning Liu, and Yuning Liao, and Hongbiao Huang, and Xianping Shi, and Lili Jiang, and Xiuhua Liu, and Q Ping Dou, and Xuejun Wang, and Jinbao Liu
July 1979, Contact dermatitis,
Chong Zhao, and Xin Chen, and Changshan Yang, and Dan Zang, and Xiaoying Lan, and Siyan Liao, and Peiquan Zhang, and Jinjie Wu, and Xiaofen Li, and Ningning Liu, and Yuning Liao, and Hongbiao Huang, and Xianping Shi, and Lili Jiang, and Xiuhua Liu, and Q Ping Dou, and Xuejun Wang, and Jinbao Liu
July 1999, Environmental research,
Chong Zhao, and Xin Chen, and Changshan Yang, and Dan Zang, and Xiaoying Lan, and Siyan Liao, and Peiquan Zhang, and Jinjie Wu, and Xiaofen Li, and Ningning Liu, and Yuning Liao, and Hongbiao Huang, and Xianping Shi, and Lili Jiang, and Xiuhua Liu, and Q Ping Dou, and Xuejun Wang, and Jinbao Liu
June 2021, International journal of molecular sciences,
Chong Zhao, and Xin Chen, and Changshan Yang, and Dan Zang, and Xiaoying Lan, and Siyan Liao, and Peiquan Zhang, and Jinjie Wu, and Xiaofen Li, and Ningning Liu, and Yuning Liao, and Hongbiao Huang, and Xianping Shi, and Lili Jiang, and Xiuhua Liu, and Q Ping Dou, and Xuejun Wang, and Jinbao Liu
December 2017, Cancer metastasis reviews,
Chong Zhao, and Xin Chen, and Changshan Yang, and Dan Zang, and Xiaoying Lan, and Siyan Liao, and Peiquan Zhang, and Jinjie Wu, and Xiaofen Li, and Ningning Liu, and Yuning Liao, and Hongbiao Huang, and Xianping Shi, and Lili Jiang, and Xiuhua Liu, and Q Ping Dou, and Xuejun Wang, and Jinbao Liu
July 2003, Archives of dermatological research,
Chong Zhao, and Xin Chen, and Changshan Yang, and Dan Zang, and Xiaoying Lan, and Siyan Liao, and Peiquan Zhang, and Jinjie Wu, and Xiaofen Li, and Ningning Liu, and Yuning Liao, and Hongbiao Huang, and Xianping Shi, and Lili Jiang, and Xiuhua Liu, and Q Ping Dou, and Xuejun Wang, and Jinbao Liu
January 2015, Cancer letters,
Chong Zhao, and Xin Chen, and Changshan Yang, and Dan Zang, and Xiaoying Lan, and Siyan Liao, and Peiquan Zhang, and Jinjie Wu, and Xiaofen Li, and Ningning Liu, and Yuning Liao, and Hongbiao Huang, and Xianping Shi, and Lili Jiang, and Xiuhua Liu, and Q Ping Dou, and Xuejun Wang, and Jinbao Liu
November 2023, iScience,
Chong Zhao, and Xin Chen, and Changshan Yang, and Dan Zang, and Xiaoying Lan, and Siyan Liao, and Peiquan Zhang, and Jinjie Wu, and Xiaofen Li, and Ningning Liu, and Yuning Liao, and Hongbiao Huang, and Xianping Shi, and Lili Jiang, and Xiuhua Liu, and Q Ping Dou, and Xuejun Wang, and Jinbao Liu
September 2018, Oncogenesis,
Chong Zhao, and Xin Chen, and Changshan Yang, and Dan Zang, and Xiaoying Lan, and Siyan Liao, and Peiquan Zhang, and Jinjie Wu, and Xiaofen Li, and Ningning Liu, and Yuning Liao, and Hongbiao Huang, and Xianping Shi, and Lili Jiang, and Xiuhua Liu, and Q Ping Dou, and Xuejun Wang, and Jinbao Liu
November 2017, Scientific reports,
Chong Zhao, and Xin Chen, and Changshan Yang, and Dan Zang, and Xiaoying Lan, and Siyan Liao, and Peiquan Zhang, and Jinjie Wu, and Xiaofen Li, and Ningning Liu, and Yuning Liao, and Hongbiao Huang, and Xianping Shi, and Lili Jiang, and Xiuhua Liu, and Q Ping Dou, and Xuejun Wang, and Jinbao Liu
January 2020, Frontiers in oncology,
Copied contents to your clipboard!